ZMYND11 Antibody

What is ZMYND11 and what experimental approaches can confirm its function?

ZMYND11 (Zinc Finger MYND-Type Containing 11) is a multidomain protein that functions as a histone reader with specificity for H3.3K36me3 modifications. It represents the first identified variant-specific reader of methylated histones that can distinguish between H3.3 and canonical H3 variants . ZMYND11 plays dual roles in transcriptional regulation (both activation and repression) and functions as a tumor suppressor in multiple cancer types .

To experimentally confirm ZMYND11's function, researchers typically employ:

• ChIP-seq analysis to map genomic binding sites (showing co-localization with H3.3K36me3)

• RNA-seq following ZMYND11 knockdown to identify regulated genes

• Co-immunoprecipitation to detect protein-protein interactions

• Xenograft mouse models to assess tumor suppressor functions

What are the key applications of ZMYND11 antibodies in epigenetic research?

ZMYND11 antibodies serve several critical applications in epigenetic research:

Multiple antibodies targeting different ZMYND11 regions are available, including N-terminal (AA 152-180, 138-187) and middle region epitopes , allowing researchers to study domain-specific functions.

How does ZMYND11 function as a histone reader and how can this be verified?

ZMYND11 functions as a specific reader of H3K36me3 on the histone variant H3.3 through its PWWP domain . The specificity for H3.3 over canonical H3 is mediated by unique hydrogen bonding interactions between ZMYND11 and H3.3, particularly involving residues R168, E251, E254, and N266 of ZMYND11 and residues A29, S31, and T32 of H3.3 .

To experimentally verify this reading function:

• Perform binding assays with recombinant PWWP domains and modified histone peptides

• Use point mutations in key residues (W294A, D307N) to disrupt binding

• Conduct ChIP-seq with ZMYND11 antibodies and compare with H3K36me3 and H3.3 distribution

• Employ SETD2 knockdown to reduce H3K36me3 levels and observe ZMYND11 binding changes

Evidence indicates that ZMYND11 densities in gene bodies directly correlate with H3K36me3 levels, and ZMYND11 binding is dependent on H3K36me3 presence, as demonstrated in SETD2 knockdown experiments .

What methodological approaches can resolve contradictions in ZMYND11's dual role in transcription?

ZMYND11 exhibits seemingly contradictory roles in both transcriptional repression and activation. RNA-seq analysis revealed 268 upregulated and 370 downregulated genes upon ZMYND11 depletion . This apparent contradiction can be methodologically addressed through:

• Integrated genomic analysis:

  • Combine RNA-seq, ChIP-seq for ZMYND11, H3.3, H3K36me3, and RNA Pol II

  • Correlate ZMYND11 binding patterns with gene expression changes

  • Analyze Pol II pausing indices at ZMYND11-bound genes

• Context-specific mechanistic studies:

  • Examine ZMYND11's association with different protein complexes using IP-MS

  • Perform PRO-seq to measure transcription elongation rates at different gene sets

  • Use targeted CUT&RUN for higher resolution binding profiles at activated vs. repressed genes

The data suggest ZMYND11 primarily functions in "fine-tuning" gene expression by modulating Pol II elongation rather than acting as a simple on/off switch . It specifically represses oncogene expression while showing diverse effects on other gene classes.

How should experiments be designed to investigate ZMYND11's noncanonical functions?

Recent research has revealed that ZMYND11 has noncanonical functions beyond histone reading, including recognizing arginine-methylated HNRNPA1 through its MYND domain . To properly investigate these functions:

• Domain-specific functional analysis:

  • Generate domain deletion constructs (particularly MYND domain deletions)

  • Compare full-length vs. domain-deleted ZMYND11 in rescue experiments

  • Perform structure-function analyses with point mutations in key domains

• Methylation-dependent interaction studies:

  • Use PRMT5 inhibitors to disrupt arginine methylation

  • Employ methylation-deficient HNRNPA1 mutants

  • Perform co-IP experiments under varying methylation conditions

  • Apply proximity ligation assays to visualize interactions in situ

• Downstream pathway analysis:

  • Monitor PKM splicing (PKM1/PKM2 ratio) as a functional readout

  • Analyze stress granule formation in cytoplasm

  • Track HNRNPA1 nuclear-cytoplasmic distribution

Experimental data shows that full-length ZMYND11, but not MYND-domain-deleted ZMYND11, inhibits PKM2 and promotes PKM1 isoform formation at both mRNA and protein levels , indicating the importance of this domain for the noncanonical function.

What are optimal protocols for ChIP-seq experiments targeting ZMYND11?

ZMYND11 ChIP-seq experiments require careful optimization due to the protein's specific reading of H3.3K36me3. Based on published methodologies :

• Antibody selection and validation:

  • Validate antibody specificity using ZMYND11 knockdown controls

  • Confirm antibody recognizes endogenous ZMYND11 by western blot

  • Test different ZMYND11 epitopes (N-terminal vs. middle region antibodies)

• Chromatin preparation optimization:

  • Adjust formaldehyde crosslinking time (typically 10-15 minutes)

  • Optimize sonication to achieve 200-500bp fragments

  • Perform dual crosslinking for improved capture of protein-protein interactions

• Data analysis considerations:

  • Compare ZMYND11 ChIP-seq signals with H3K36me3 and H3.3 profiles

  • Analyze gene body enrichment patterns, particularly in transcribed regions

  • Correlate with RNA Pol II density and elongation markers

• Controls and validation:

  • Include ZMYND11-depleted samples as negative controls

  • Perform ChIP-qPCR validation at key loci

  • Compare ZMYND11 binding in SETD2 knockdown cells (reduced H3K36me3)

Published ChIP-seq data shows high ZMYND11 occupancy in genes enriched with both H3K36me3 and H3.3, while occupancy is much lower in genes decorated with only H3K36me3 or only H3.3 .

How can researchers assess ZMYND11's tumor suppressor function in experimental models?

ZMYND11 exhibits tumor suppressor functions that depend on its H3.3K36me3-binding activity. Comprehensive assessment requires multiple complementary approaches:

• In vitro functional assays:

  • Colony formation assays comparing wild-type vs. binding-deficient mutants

  • Cell proliferation and survival assays in cancer cell lines

  • Migration and invasion assays (especially for metastatic potential)

  • Use multiple cell models (published studies used U2OS, MDA-MB-231, and prostate cancer lines)

• In vivo tumor models:

  • Xenograft studies comparing cells expressing wild-type vs. mutant ZMYND11

  • Monitor tumor volume and weight over time

  • Use bioluminescent imaging for detecting metastasis

  • Analyze circulating tumor cells in blood samples

• Molecular mechanism analysis:

  • Identify ZMYND11-regulated oncogenes through RNA-seq

  • Assess Pol II elongation at specific oncogenes

  • Evaluate PKM splicing (PKM1/PKM2 ratio) as a metabolic readout

  • Monitor stress granule formation

Published data shows that wild-type ZMYND11 overexpression inhibits tumor cell growth, while H3.3K36me3 binding-deficient mutants (W294A) and cancer-associated mutations (D307N) are severely impaired in suppressing cell proliferation and tumor growth in vivo . Notably, ZMYND11 knockdown significantly promoted lung metastasis in mouse models .

What methodological approaches can determine if ZMYND11 has clinical relevance as a biomarker?

The clinical relevance of ZMYND11 as a potential biomarker or therapeutic target can be assessed through:

• Patient sample analysis:

  • Perform IHC staining of ZMYND11 in tumor tissue microarrays

  • Compare ZMYND11 expression in tumor vs. adjacent non-tumor tissues

  • Correlate expression with clinical parameters and outcomes

• Survival analysis approaches:

  • Kaplan-Meier survival analysis stratified by ZMYND11 expression

  • Cox regression for multivariate analysis including other clinicopathological factors

  • Analysis across multiple independent patient cohorts

• Functional validation in patient-derived models:

  • Test ZMYND11 restoration in low-expressing patient-derived xenografts

  • Evaluate sensitivity to PRMT5 inhibitors in ZMYND11-low tumors

  • Analyze combination therapies targeting ZMYND11-regulated pathways

Clinical data demonstrates that ZMYND11 is downregulated in multiple human cancers including breast cancer and prostate cancer . Importantly, low ZMYND11 expression levels in breast cancer patients correlate with worse disease-free survival , and patients with lower ZMYND11 expression had increased risk for postoperative biochemical recurrence in prostate cancer .

How should researchers troubleshoot ZMYND11 detection issues in Western blotting?

When troubleshooting detection issues with ZMYND11 antibodies in Western blotting:

• Protein extraction optimization:

  • Use nuclear extraction protocols (ZMYND11 is primarily nuclear)

  • Include protease and phosphatase inhibitors

  • Test different lysis buffers (RIPA vs. NP-40 vs. triton-based)

• Antibody selection considerations:

  • Choose antibodies targeting different epitopes (N-terminal, middle region)

  • Validate with positive controls (cell lines with known ZMYND11 expression)

  • Test different antibody concentrations (typically 1:500-1:2000)

  • Consider overnight incubation at 4°C for primary antibody

• Sample preparation factors:

  • Avoid excessive heat during denaturation (65°C for 10 minutes instead of boiling)

  • Use fresh samples when possible

  • Load adequate protein amount (50-100 μg for cell lysates)

• Detection system variables:

  • Try enhanced chemiluminescence systems for improved sensitivity

  • Consider fluorescent secondary antibodies for quantitative analysis

  • Increase exposure time incrementally to detect weak signals

ZMYND11 antibodies have been successfully applied in Western blotting across multiple studies, with commercially available options targeting various epitopes including AA 152-180 and AA 138-187 from the N-terminal region .

What are key considerations for optimizing ZMYND11 immunohistochemistry on tissue samples?

For optimal ZMYND11 detection in tissue samples by IHC:

• Tissue preparation and antigen retrieval:

  • Test different fixation times with 10% neutral buffered formalin

  • Compare heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0) vs. EDTA buffer (pH 9.0)

    • Microwave vs. pressure cooker retrieval

  • Optimize retrieval time (typically 15-20 minutes)

• Antibody optimization:

  • Titrate antibody concentration (typically 1:100-1:500)

  • Test overnight incubation at 4°C vs. 1-2 hours at room temperature

  • Include positive tissue controls (normal tissues with known ZMYND11 expression)

  • Use ZMYND11 knockdown tissues as negative controls

• Signal detection considerations:

  • Compare DAB (brown) vs. AEC (red) chromogens

  • Test amplification systems for weak signals (ABC, polymer detection)

  • Optimize counterstaining intensity with hematoxylin

• Scoring and analysis approaches:

  • Develop consistent scoring system (H-score, percentage positive, intensity)

  • Consider automated image analysis for quantification

  • Separately evaluate nuclear vs. cytoplasmic staining

Published studies have successfully employed IHC staining of ZMYND11 in tumor tissue microarrays using antibodies reactive to human ZMYND11 , showing decreased protein levels in prostate cancer patient samples compared with surrounding non-tumor tissues.

How can researchers investigate the relationship between ZMYND11 and alternative splicing mechanisms?

ZMYND11 has been implicated in regulating alternative splicing, particularly of PKM pre-mRNA. To investigate this emerging function:

• RNA splicing analysis approaches:

  • Perform RNA-seq with focus on alternative splicing events

  • Use PCR with isoform-specific primers for targeted analysis

  • Employ minigene splicing reporters for mechanistic studies

  • Analyze relative abundance of PKM1 and PKM2 isoforms

• Molecular mechanism investigation:

  • Study ZMYND11 interaction with HNRNPA1 and other splicing factors

  • Determine domain requirements (particularly MYND domain)

  • Investigate methylation dependence of these interactions

  • Analyze binding to pre-mRNA using CLIP-seq

• Functional consequence assessment:

  • Measure metabolic parameters (glycolysis vs. oxidative phosphorylation)

  • Analyze tumor cell phenotypes (proliferation, migration, stress response)

  • Determine sensitivity to metabolic inhibitors

Research has shown that full-length ZMYND11, but not MYND-domain-deleted ZMYND11, inhibits PKM2 and promotes PKM1 isoform formation at both mRNA and protein levels . ZMYND11 also blocks the stimulatory effects of HNRNPA1 on PKM2 formation, suggesting an inhibitory effect on HNRNPA1-mediated PKM splicing .

What experimental designs can assess the therapeutic potential of targeting ZMYND11 pathways?

To assess therapeutic potential of targeting ZMYND11-related pathways:

• Restoration approaches in ZMYND11-low tumors:

  • Gene therapy models with ZMYND11 re-expression

  • Small molecules that mimic ZMYND11 reader function

  • Drugs that upregulate endogenous ZMYND11 expression

• Synthetic lethality screening:

  • Perform CRISPR screens in ZMYND11-low vs. normal cells

  • Identify vulnerabilities created by ZMYND11 loss

  • Test drug combinations targeting compensatory pathways

• Targeting downstream effectors:

  • Investigate PKM2 inhibitors in ZMYND11-low tumors

  • Assess PRMT5 inhibitors that disrupt ZMYND11-HNRNPA1 interaction

  • Test transcriptional elongation inhibitors in context of ZMYND11 status

Research has demonstrated that ZMYND11-low expressing tumors show sensitivity to PRMT5 inhibitor treatment , suggesting a therapeutic opportunity. The connection between ZMYND11 and the PKM2/PKM1 ratio also suggests potential for metabolic targeting approaches.